20 year open-label extension study of Copaxone 20 mg daily

[MSUK]

Results released for 20 year open-label extension study of Copaxone 20 mg daily for RRMS

Teva Pharmaceutical Industries Ltd. announced further results from a long-term, open-label extension study of glatiramer acetate (GA). The extension study was designed to evaluate the long-term neurologic disease course, and the safety and efficacy of glatiramer acetate 20 mg daily, the therapeutic agent in Copaxone(R) (glatiramer acetate injection), which is indicated for reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis (RRMS). Detailed study results will be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark during poster session P577 on October 3, 2013...... Read More - http://www.ms-uk.org/copaxone